PURPOSE: Fibroblast growth factor receptor 4 (FGFR4) is a member of a family of transmembrane receptors with ligand-induced tyrosine kinase activity. The Gly388Arg polymorphism in the FGFR4 gene was reported to modulate cancer cell migration in vitro and to be associated with breast, colon, and prostate cancer prognostic parameters. The purpose of this study was to investigate the involvement of the FGFR4 polymorphism in lung tumorigenesis. PATIENTS AND METHODS: A case-control study was performed including 274 patients with histologically confirmed lung adenocarcinoma and 401 healthy control subjects from general population. mRNA expression analysis was carried out in healthy lung of cancer patients. RESULTS: Patients with the Arg/Arg or Gly/Arg genotype compared to those with a Gly/Gly genotype had an earlier age at cancer onset (median age, 60.2 v 63.4 years), higher proportion of poor clinical stage disease (hazard ratio [HR], 2.3; 95% CI, 1.4 to 3.9; P = .002), of nodal involvement (HR, 1.9; 95% CI, 1.1 to 3.2; P = .027), or of short-term survivors (HR, 1.6; 95% CI, 1.1 to 2.3; P = .008). In healthy lungs, FGFR4 did not show allele-specific expression and mRNA levels were not associated with genotype. CONCLUSION: This study suggests that FGFR4 Gly388Arg polymorphism may predict prognosis in lung adenocarcinoma.
PURPOSE:Fibroblast growth factor receptor 4 (FGFR4) is a member of a family of transmembrane receptors with ligand-induced tyrosine kinase activity. The Gly388Arg polymorphism in the FGFR4 gene was reported to modulate cancer cell migration in vitro and to be associated with breast, colon, and prostate cancer prognostic parameters. The purpose of this study was to investigate the involvement of the FGFR4 polymorphism in lung tumorigenesis. PATIENTS AND METHODS: A case-control study was performed including 274 patients with histologically confirmed lung adenocarcinoma and 401 healthy control subjects from general population. mRNA expression analysis was carried out in healthy lung of cancerpatients. RESULTS:Patients with the Arg/Arg or Gly/Arg genotype compared to those with a Gly/Gly genotype had an earlier age at cancer onset (median age, 60.2 v 63.4 years), higher proportion of poor clinical stage disease (hazard ratio [HR], 2.3; 95% CI, 1.4 to 3.9; P = .002), of nodal involvement (HR, 1.9; 95% CI, 1.1 to 3.2; P = .027), or of short-term survivors (HR, 1.6; 95% CI, 1.1 to 2.3; P = .008). In healthy lungs, FGFR4 did not show allele-specific expression and mRNA levels were not associated with genotype. CONCLUSION: This study suggests that FGFR4 Gly388Arg polymorphism may predict prognosis in lung adenocarcinoma.
Authors: Yutaka Maeda; Tomoshi Tsuchiya; Haiping Hao; David H Tompkins; Yan Xu; Michael L Mucenski; Lingling Du; Angela R Keiser; Takuya Fukazawa; Yoshio Naomoto; Takeshi Nagayasu; Jeffrey A Whitsett Journal: J Clin Invest Date: 2012-11-12 Impact factor: 14.808
Authors: Monica Spinola; Felicia S Falvella; Francesca Colombo; James P Sullivan; David S Shames; Luc Girard; Paola Spessotto; John D Minna; Tommaso A Dragani Journal: Mol Cancer Date: 2010-03-17 Impact factor: 27.401
Authors: L M FitzGerald; E Karlins; D M Karyadi; E M Kwon; J S Koopmeiners; J L Stanford; E A Ostrander Journal: Prostate Cancer Prostatic Dis Date: 2008-09-02 Impact factor: 5.554
Authors: Nao Souma; Tamara Isakova; David Lipiszko; Ralph L Sacco; Mitchell S V Elkind; Janet T DeRosa; Shonni J Silverberg; Armando J Mendez; Chuanhui Dong; Clinton B Wright; Myles Wolf Journal: J Clin Endocrinol Metab Date: 2016-08-08 Impact factor: 5.958